Werewolf therapeutics to participate in the 7th annual evercore isi healthconx healthcare conference

Watertown, mass., nov. 20, 2024 (globe newswire) -- werewolf therapeutics, inc. (the “company” or “werewolf”) (nasdaq: howl), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions, today announced that daniel j. hicklin, ph.d., president and chief executive officer of werewolf, and randi isaacs, m.d., chief medical officer of werewolf, will participate in a fireside chat at 12:55 pm et on thursday, december 5, 2024, at the 7th annual evercore isi healthconx healthcare conference, taking place december 3-5 in miami, florida.
EVR Ratings Summary
EVR Quant Ranking